Multiple studies using PARP inhibitors in various tumor models found that PARP inhibitors could sensitize tumor cells to cytotoxic therapies such as temozolomide, topoisomerase I inhibitors, platinum-based chemotherapeutics, and radiation treatment [13–15]. The gene discussed is PARP1; the disease is neoplasm.